TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06316778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: 12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
Study: NCT06124183

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals
Description: The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals
Description: The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
Study: NCT04531878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Phenylbutyrate
Description: 4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
Study: NCT05545020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent chromium versus synthetic and/ or biological DMARDs
Description: Supplement and immunesuppressants
Study: NCT05621213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation assisted by a physiotherapist or nurse
Description: A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.
Study: NCT05892822

Intervention type: OTHER
Intervention: Amyotrophic Lateral Sclerosis
Description: All ALS patients included in this group.
Study: NCT05453396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV
Study: NCT06376422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spongioflex®
Description: partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.

Intervention type: OTHER
Group type: OTHER
Intervention: non-operated
Description: no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
Study: NCT04810247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Project
Description: The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
Study: NCT06514755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GNA followed by GAE
Description: Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GAE alone
Description: Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
Study: NCT06113341

Intervention type: DRUG
Intervention: IDegLira
Description: Pre-filled pen injection.
Study: NCT06505135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem-cell treatment
Description: In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
Study: NCT04696861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEAS for Hope
Description: Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care (Safety Planning)
Description: Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
Study: NCT04868851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Here for Health Only
Description: Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth technology assisted exercise counselling
Description: Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
Study: NCT06579404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy with glucose sensor
Description: Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
Study: NCT06163040

Intervention type: DRUG
Intervention: Elotuzumab in combination with pomalidomide and dexamethasone
Description: Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)

Intervention type: DRUG
Intervention: Elotuzumab in combination with lenalidomide and dexamethasone
Description: Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
Study: NCT05726942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthi
Description: Healthi refers to the Healthi app, which is a mobile application for weight loss
Study: NCT06368804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic monotherapy treatment and follow-up
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic bitherapy treatment and follow-up
Description: 1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa).
Study: NCT06356974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)
Description: Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
Study: NCT04622761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)
Study: NCT06400706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG guided general anesthesia
Description: EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
Study: NCT05591924

Intervention type: PROCEDURE
Intervention: Phelebotomy
Description: Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube

Intervention type: PROCEDURE
Intervention: Phelebotomy
Description: Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
Study: NCT06162065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin Pill
Description: pharmacological antimuscarinic treatment
Study: NCT05591924

Intervention type: PROCEDURE
Intervention: Broncheoalveolar Lavage
Description: Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.

Intervention type: PROCEDURE
Intervention: Tracheal Aspirate
Description: Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.

Intervention type: PROCEDURE
Intervention: Rectal Swab
Description: A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
Study: NCT06162065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Pill
Description: pharmacological antimuscarinic treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boldo supplement
Description: treatment supplemented with boldo
Study: NCT05900401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant
Description: Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Collection
Description: PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab on study day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
Study: NCT05307185

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tritordeum-based food
Description: Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tritordeum-based food
Description: Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tritordeum-based food
Description: Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
Study: NCT06646874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR game
Description: Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
Study: NCT04748471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccine
Study: NCT05615896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging Session
Description: Various scans will be captured on both devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging Session
Description: Various scans will be captured on both devices
Study: NCT05825547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Description: Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
Study: NCT05069844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum chewing for 2 minutes
Description: In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum chewing for 4 minutes
Description: In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
Study: NCT06398171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
Study: NCT05310058

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C6 ketone di-ester
Description: C6 ketone di-ester
Study: NCT05762471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive GSBR-1290 or matching Placebo
Study: NCT04412837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical CBD Patch
Description: 35 mg CBD patch
Study: NCT04800133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran
Description: mRNA vaccine developed by BioNTech against COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran
Description: mRNA vaccine developed by BioNTech against COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac
Description: Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac, intradermal
Description: Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
Study: NCT06280118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue
Description: Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
Study: NCT04412837

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Identical patch without active ingredient.
Study: NCT06048939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity aerobic training and body weight resistance training
Description: Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity aerobic training
Description: Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises